An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
about
New Therapeutic Concept of NAD Redox Balance for Cisplatin NephrotoxicityMechanism of Platinum Derivatives Induced Kidney InjuryPathophysiological role of different tubular epithelial cell death modes in acute kidney injuryProteomic candidate biomarkers of drug-induced nephrotoxicity in the ratExtract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathwaySoluble extract from Moringa oleifera leaves with a new anticancer activityMitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in miceNephroCheck data compared to serum creatinine in various clinical settingsPathophysiology of cisplatin-induced acute kidney injury.A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumoursPuerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathwayLower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.Renal integrin-linked kinase depletion induces kidney cGMP axis upregulation: Consequences on basal and acutely damaged renal functionMetformin Protects Against Cisplatin-Induced Tubular Cell Apoptosis and Acute Kidney Injury via AMPKα-regulated Autophagy Induction.A Comprehensive Review on the Genetic Regulation of Cisplatin-induced NephrotoxicityBridging translation for acute kidney injury with better preclinical modeling of human diseaseNovel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.The effect of thymoquinone treatment on the combined renal and pulmonary toxicity of cisplatin and diesel exhaust particlesERK-mediated suppression of cilia in cisplatin-induced tubular cell apoptosis and acute kidney injury.Heat shock factor 1 induces crystallin-αB to protect against cisplatin nephrotoxicity.Resveratrol attenuates acute kidney injury by inhibiting death receptor‑mediated apoptotic pathways in a cisplatin‑induced rat model.Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity.CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury.Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy.Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update.Cisplatin : an old drug with a newfound efficacy -- from mechanisms of action to cytotoxicity.Cisplatin-induced renal toxicity magn…ified: role of magnesium deficiency in AKI onset.Biliverdin protects against cisplatin-induced apoptosis of renal tubular epithelial cells.Blockade of KCa3.1 potassium channels protects against cisplatin-induced acute kidney injury.Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures.Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation.DNA damage response in nephrotoxic and ischemic kidney injury.Mitogen-Activated Protein Kinase 14 Promotes AKI.Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer PropertiesAntiproliferative and Apoptosis Induction Potential of the Methanolic Leaf Extract of Holarrhena floribunda (G. Don).Use of sodium bicarbonate to promote weight gain, maintain body temperature, normalize renal functions and minimize mortality in rodents receiving the chemotherapeutic agent cisplatin.Vascular remodelling in the pulmonary circulation after major lung resectionAntitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
P2860
Q26765483-FE46F1CF-383E-4D6C-A8AD-9FF58680004EQ26783436-E42FCD14-C818-4022-946E-80C663DB3B8CQ26785893-ECD34799-34C9-4F37-9B95-1D3BD83DD4AEQ27305109-A4B7D716-FB34-4119-BB08-1369CAAF1501Q28481696-20436656-EDBA-4A1A-859D-C3931DA7D05FQ28538048-FB2B9CC4-6B3F-41B5-90CE-7CECB1AE1D09Q28546437-472A64EC-FC23-42B6-BC5D-A6191239E0D8Q31031264-D8C4D0F4-EC65-49B2-B1FD-5CA6EDF1FF55Q34073302-0EDFCD82-EC7E-48AD-A0BF-4DEC88E69726Q36166846-FAF403F7-59D2-401B-98F2-0E105EC9EE91Q36275825-DA4C2334-AD0E-4460-B2B5-4D3937F1F5C1Q36285665-54E553FA-00A2-4E29-9CD1-FFCA0852DC93Q36412220-97D76907-1B94-4A9D-9577-084C329E7C8CQ36758028-89C965D1-C795-47B4-B58E-CD0D9635AB69Q36774352-9BFB7077-8308-4731-A29C-4EED9852E816Q36906569-8AC94C1E-8344-4B60-A727-4CC770A086A9Q36957116-5BBA9F5C-06AB-4D2C-9F3E-68DC85BF24A0Q37022931-2D12D476-6D63-4E08-9BDF-5E59E872C80CQ37071354-7AC44556-41CD-45DA-ADEB-9F529246943CQ37118337-D5227B70-5BC1-45D6-8EDE-DF89E0BB5618Q37139438-620EA616-EC47-476F-818B-8EB50D6B7C1AQ37297507-D7CFB5A9-5E39-4164-8B4C-0350FA0790C9Q37299627-A960C8BF-B7F5-4C7F-9145-CE108A09B301Q37575488-1C59A6E1-ED91-4904-B735-364081B781B0Q37624426-DF7D2074-49A4-4117-9443-FBB8CC22B369Q37989844-01FD0EFD-1FC1-4CE8-B7EC-BADCDCEBC3ECQ38123245-22C7A64C-AC41-4D71-B3B3-648EBEF675D1Q38618836-7FE3CF64-4FC0-46C9-A255-E9C71F8D9B1BQ38797217-A22401B2-371A-49FB-8AB1-1AC5033E959FQ38830162-236F45B4-8D2E-4345-998E-4CFEAD81C257Q38878449-15A8A0DF-54CC-4974-A291-DD839E02FF7EQ38975452-CBAB2721-1B7E-4A77-8B1E-B98444A64457Q38983107-AB05C84A-45A0-494C-8339-032FBD8CE9FEQ39041331-90478DA5-8373-4D15-A63B-8723C13985E0Q39398586-E74FDA5B-A466-4583-8D83-32DEC67888C2Q39933592-E05DE346-88B0-4DB4-89BF-884CB61D7B16Q42000331-D756D126-350C-429A-9D62-E169AE48A479Q42147217-0F6080BC-3E07-4CF7-9757-4C597ECEEE47Q42356269-E968BB13-50CA-4AD5-8F2E-29A3A53A5DEFQ43974504-8F5D0814-01AC-4454-A34F-A55AB64CD84F
P2860
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
@en
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
@nl
type
label
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
@en
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
@nl
prefLabel
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
@en
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
@nl
P2093
P1476
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
@en
P2093
Ana I Morales
Francisco J López-Hernández
Penélope D Sánchez-González
P304
P356
10.3109/10408444.2011.602662
P407
P577
2011-08-12T00:00:00Z